Arnaud Carpentier

Dr. Arnaud Carpentier

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2010 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EHEva Herker
Eva Herker
CHCharles Harris
Charles Harris
CHCéline Hernandez
Céline Hernandez
ACArnaud Carpentier
Arnaud Carpentier
KKKatrin Kaehlcke
Katrin Kaehlcke
MOMelanie Ott
Melanie Ott
Infectious hepatitis C virus (HCV) particles assemble near lipid droplets in infected cells. Herker et al. now report that diacylglycerol acyltransferase-1 (DGAT1) is required for this process and show that inhibiting DGAT1 reduces HCV infectivity in vitro. Targeting DGAT1 might offer a new strategy for the control of HCV infection. Hepatitis C virus (HCV) infection is closely tied to the lipid metabolism of liver cells. Here we identify the triglyceride-synthesizing enzyme diacylglycerol acyltransferase-1 (DGAT1) as a key host factor for HCV infection. DGAT1 interacts with the viral nucleocapsid core and is required for the trafficking of core to lipid droplets. Inhibition of DGAT1 activity or RNAi-mediated knockdown of DGAT1 severely impairs infectious virion production, implicating DGAT1 as a new target for antiviral therapy.

1 October 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
PPPhilippe Podevin
Philippe Podevin
ACArnaud Carpentier
Arnaud Carpentier
VPVéronique Pène
Véronique Pène
LALynda Aoudjehane
Lynda Aoudjehane
MCMatthieu Carrière
Matthieu Carrière
YCYvon Calmus
Yvon Calmus

8 October 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ACArnaud Carpentier
Arnaud Carpentier
ATAbeba Tesfaye
Abeba Tesfaye
VCVirginia Chu
Virginia Chu
INIla Nimgaonkar
Ila Nimgaonkar
FZFang Zhang
Fang Zhang
TLT.Jake Liang
T.Jake Liang
The demonstrated ability to differentiate both human embryonic stem cells (hESCs) and patient-derived induced pluripotent stem cells (hiPSCs) into hepatocyte-like cells (HLCs) holds great promise for both regenerative medicine and liver disease research. Here, we determined that, despite an immature phenotype, differentiated HLCs are permissive to hepatitis C virus (HCV) infection and mount an interferon response to HCV infection in vitro. HLCs differentiated from hESCs and hiPSCs could be engrafted in the liver parenchyma of immune-deficient transgenic mice carrying the urokinase-type plasminogen activator gene driven by the major urinary protein promoter. The HLCs were maintained for more than 3 months in the livers of chimeric mice, in which they underwent further maturation and proliferation. These engrafted and expanded human HLCs were permissive to in vivo infection with HCV-positive sera and supported long-term infection of multiple HCV genotypes. Our study demonstrates efficient engraftment and in vivo HCV infection of human stem cell–derived hepatocytes and provides a model to study chronic HCV infection in patient-derived hepatocytes, action of antiviral therapies, and the biology of HCV infection.

1 March 2017 in Journal of Hepatology
Verified
Journal Article
Closed access
YXYuchen Xia
Yuchen Xia
ACArnaud Carpentier
Arnaud Carpentier
XCXiaoming Cheng
Xiaoming Cheng
PBPeter Daniel Block
Peter Daniel Block
YZYao Zhao
Yao Zhao
TLT.Jake Liang
T.Jake Liang

1 May 2016 in Stem Cell Research
Verified
Journal Article
Open access
ACArnaud Carpentier
Arnaud Carpentier
INIla Nimgaonkar
Ila Nimgaonkar
VCVirginia Chu
Virginia Chu
YXYuchen Xia
Yuchen Xia
ZHZongyi Hu
Zongyi Hu
TLT.Jake Liang
T.Jake Liang
The establishment of protocols to differentiate human pluripotent stem cells (hPSCs) including embryonic (ESC) and induced pluripotent (iPSC) stem cells into functional hepatocyte-like cells (HLCs) creates new opportunities to study liver metabolism, genetic diseases and infection of hepatotropic viruses (hepatitis B and C viruses) in the context of specific genetic background. While supporting efficient differentiation to HLCs, the published protocols are limited in terms of differentiation into fully mature hepatocytes and in a smaller-well format. This limitation handicaps the application of these cells to high-throughput assays. Here we describe a protocol allowing efficient and consistent hepatic differentiation of hPSCs in 384-well plates into functional hepatocyte-like cells, which remain differentiated for more than 3weeks. This protocol affords the unique opportunity to miniaturize the hPSC-based differentiation technology and facilitates screening for molecules in modulating liver differentiation, metabolism, genetic network, and response to infection or other external stimuli.

1 October 2009 in Transplantation Proceedings
Verified
Journal Article
Closed access
CMC. Miroux
C. Miroux
OMOlivier Morales
Olivier Morales
ACArnaud Carpentier
Arnaud Carpentier
SDS. Dharancy
S. Dharancy
FCF. Conti
F. Conti
NDN. Delhem
N. Delhem